Invivyd and SPEAR Study Group Announce Phase 2 Clinical Trial!
Exciting News!
Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome - Invivyd
NEW HAVEN, Conn., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) and the SPEAR Study Group today announced the initiation of FLINTLOCK, a Phase 2 clinical trial evaluating the safety, tolerability, pharmacokinetics, and clinical efficacy of high-dose monoclonal antibody VYD2311 in individuals with Long COVID or Post-Vaccination Syndrome (PVS), also known as COVID vaccine injury.
“Long COVID continues to be a significant challenge for millions of Americans. It is a disease state characterized by persistent and debilitating symptoms impacting multiple systems across the human body, including immune dysfunction, cardiovascular issues, respiratory challenges, nervous system dysfunction, pain, and other health issues that can impact a person’s day-to-day life,” noted David Putrino, Ph.D., Nash Family Director of the Cohen Center for Recovery from Complex Chronic Illness at Mount Sinai and Founding Member of the SPEAR Study Group. “We are excited to take the next step in advancing this potential therapeutic option for patients living with Long COVID or Post-Vaccination Syndrome, a diagnosis which has received very little attention.”
Initial data expected in mid-2027.